{"downloaded": true, "htmlmade": false, "full": {"id": "29643105", "source": "MED", "pmid": "29643105", "pmcid": "PMC5916006", "fullTextIdList": {"fullTextId": "PMC5916006"}, "doi": "10.1182/bloodadvances.2018015925", "title": "A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with <i>FLT3</i>-ITD mutations.", "authorString": "Levis MJ, Perl AE, Altman JK, Gocke CD, Bahceci E, Hill J, Liu C, Xie Z, Carson AR, McClain V, Stenzel TT, Miller JE.", "authorList": {"author": [{"fullName": "Levis MJ", "firstName": "Mark J", "lastName": "Levis", "initials": "MJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD."}}}, {"fullName": "Perl AE", "firstName": "Alexander E", "lastName": "Perl", "initials": "AE", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Pennsylvania-Abramson Comprehensive Cancer Center, Philadelphia, PA."}}}, {"fullName": "Altman JK", "firstName": "Jessica K", "lastName": "Altman", "initials": "JK", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL."}}}, {"fullName": "Gocke CD", "firstName": "Christopher D", "lastName": "Gocke", "initials": "CD", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD."}}}, {"fullName": "Bahceci E", "firstName": "Erkut", "lastName": "Bahceci", "initials": "E", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Astellas Pharma Global Development, Northbrook, IL; and."}}}, {"fullName": "Hill J", "firstName": "Jason", "lastName": "Hill", "initials": "J", "authorId": {"@type": "ORCID", "#text": "0000-0003-2512-1661"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Astellas Pharma Global Development, Northbrook, IL; and."}}}, {"fullName": "Liu C", "firstName": "Chaofeng", "lastName": "Liu", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Astellas Pharma Global Development, Northbrook, IL; and."}}}, {"fullName": "Xie Z", "firstName": "Zhiyi", "lastName": "Xie", "initials": "Z", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Invivoscribe, Inc, San Diego, CA."}}}, {"fullName": "Carson AR", "firstName": "Andrew R", "lastName": "Carson", "initials": "AR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Invivoscribe, Inc, San Diego, CA."}}}, {"fullName": "McClain V", "firstName": "Valerie", "lastName": "McClain", "initials": "V", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Invivoscribe, Inc, San Diego, CA."}}}, {"fullName": "Stenzel TT", "firstName": "Timothy T", "lastName": "Stenzel", "initials": "TT", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Invivoscribe, Inc, San Diego, CA."}}}, {"fullName": "Miller JE", "firstName": "Jeffrey E", "lastName": "Miller", "initials": "JE", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Invivoscribe, Inc, San Diego, CA."}}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0003-2512-1661"}}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "8", "volume": "2", "journalIssueId": "2672065", "dateOfPublication": "2018 Apr", "monthOfPublication": "4", "yearOfPublication": "2018", "printPublicationDate": "2018-04-01", "journal": {"title": "Blood advances", "ISOAbbreviation": "Blood Adv", "medlineAbbreviation": "Blood Adv", "NLMid": "101698425", "ISSN": "2473-9529", "ESSN": "2473-9537"}}, "pubYear": "2018", "pageInfo": "825-831", "abstractText": "Internal tandem duplications in <i>fms-like tyrosine kinase 3</i> (<i>FLT3-</i>ITDs) are common in acute myeloid leukemia (AML) and confer a poor prognosis. A sensitive and specific assay for the detection of minimal residual disease (MRD) in <i>FLT3-</i>ITD mutated AML could guide therapy decisions. Existing assays for MRD in <i>FLT3-</i>ITD AML have not been particularly useful because of limited sensitivity. We developed a sensitive and specific MRD assay for <i>FLT3-</i>ITD mutations using next-generation sequencing. The initial validation of this assay was performed by spiking fixed amounts of mutant DNA into wild-type DNA to establish a sensitivity of detection equivalent to \u22651 <i>FLT3-</i>ITD-containing cell in 10\u2009000, with a minimum input of 100\u2009000 cell equivalents of DNA. We subsequently validated the assay in bone marrow samples from patients with <i>FLT3-</i>ITD AML in remission. Finally, we analyzed bone marrow samples from 80 patients with <i>FLT3-</i>ITD relapsed/refractory AML participating in a trial of a novel FLT3 inhibitor, gilteritinib, and demonstrated a relationship between the mutation burden, as detected by the assay, and overall survival. This novel MRD assay is specific and 2 orders of magnitude more sensitive than currently available polymerase chain reaction- or next-generation sequencing-based <i>FLT3-</i>ITD assays. The assay is being prospectively validated in ongoing randomized clinical trials.", "affiliation": "Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Clinical Trial, Phase I", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"grantId": "UM1 CA186716", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "UM1 CA186691", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "P50 CA100632", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Bone Marrow", "meshQualifierList": {"meshQualifier": {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Neoplasm, Residual", "meshQualifierList": {"meshQualifier": {"abbreviation": "DI", "qualifierName": "diagnosis", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Aniline Compounds", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Pyrazines", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Survival Rate"}, {"majorTopic_YN": "N", "descriptorName": "Tandem Repeat Sequences"}, {"majorTopic_YN": "N", "descriptorName": "fms-Like Tyrosine Kinase 3", "meshQualifierList": {"meshQualifier": {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Leukemia, Myeloid, Acute", "meshQualifierList": {"meshQualifier": {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "High-Throughput Nucleotide Sequencing", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "Y"}}}]}, "chemicalList": {"chemical": [{"name": "Aniline Compounds", "registryNumber": "0"}, {"name": "Pyrazines", "registryNumber": "0"}, {"name": "FLT3 protein, human", "registryNumber": "EC 2.7.10.1"}, {"name": "fms-Like Tyrosine Kinase 3", "registryNumber": "EC 2.7.10.1"}, {"name": "gilteritinib", "registryNumber": "0"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/bloodadvances.2018015925"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5916006"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5916006?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/bloodadvances.2018015925"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "26", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-03-08", "dateOfCreation": "2018-04-13", "firstIndexDate": "2018-04-13", "fullTextReceivedDate": "2020-07-08", "dateOfRevision": "2021-06-30", "firstPublicationDate": "2018-04-01"}, "abstract": "Internal tandem duplications in <i>fms-like tyrosine kinase 3</i> (<i>FLT3-</i>ITDs) are common in acute myeloid leukemia (AML) and confer a poor prognosis. A sensitive and specific assay for the detection of minimal residual disease (MRD) in <i>FLT3-</i>ITD mutated AML could guide therapy decisions. Existing assays for MRD in <i>FLT3-</i>ITD AML have not been particularly useful because of limited sensitivity. We developed a sensitive and specific MRD assay for <i>FLT3-</i>ITD mutations using next-generation sequencing. The initial validation of this assay was performed by spiking fixed amounts of mutant DNA into wild-type DNA to establish a sensitivity of detection equivalent to \u22651 <i>FLT3-</i>ITD-containing cell in 10\u2009000, with a minimum input of 100\u2009000 cell equivalents of DNA. We subsequently validated the assay in bone marrow samples from patients with <i>FLT3-</i>ITD AML in remission. Finally, we analyzed bone marrow samples from 80 patients with <i>FLT3-</i>ITD relapsed/refractory AML participating in a trial of a novel FLT3 inhibitor, gilteritinib, and demonstrated a relationship between the mutation burden, as detected by the assay, and overall survival. This novel MRD assay is specific and 2 orders of magnitude more sensitive than currently available polymerase chain reaction- or next-generation sequencing-based <i>FLT3-</i>ITD assays. The assay is being prospectively validated in ongoing randomized clinical trials.", "journaltitle": "Blood advances", "authorinfo": ["Levis MJ", "Perl AE", "Altman JK", "Gocke CD", "Bahceci E", "Hill J", "Liu C", "Xie Z", "Carson AR", "McClain V", "Stenzel TT", "Miller JE"], "title": "A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with <i>FLT3</i>-ITD mutations."}